MCMedicalCodingSoftware
Free trial
XT25XE5

XT25XE5 — Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5

Billable / specific codeICD-10-PCS

CMS abbreviated title: Monitor Kidney w Fluor Pyraz, Extern, New Tech 5

How XT25XE5 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. TBody systemWhich system it acts on
  3. 2Root operationThe objective — the verb of the procedure
  4. 5Body partThe specific site
  5. XApproachHow the site was reached
  6. EDeviceWhat was left in place, if anything
  7. 5QualifierA further distinction where one applies

Codes near XT25XE5

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XRHD3FAInsertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Approach, New Technology Group 10
  • XRHD4FAInsertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Endoscopic Approach, New Technology Group 10
  • XRRG0L8Replacement of Right Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8
  • XRRG0M8Replacement of Right Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8
  • XRRH0L8Replacement of Left Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8
  • XRRH0M8Replacement of Left Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8
  • XT25XE5Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5
  • XW00X27Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
  • XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
  • XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
ICD-10-PCSFY2026